1.
Haematologica
; 93(3): 475-6, 2008 Mar.
Article
in English
| MEDLINE
| ID: mdl-18310545
ABSTRACT
The combination of high dose methylprednisolone and rituximab induces superior overall (93%) and complete (14%) response rates compared to high dose methylprednisolone alone (overall 43%, complete remission 0%) in heavily pre-treated chronic lymphocytic leukemia patients with advanced disease. Despite its efficacy the combination is not easily manageable because of the high rate of opportunistic infections.